Aragen Life Sciences Limited
DRHP · filed 01 Sept 2026
This is a draft. SEBI has not cleared it, there is no final price yet, and it may never become an IPO.
Aragen Life Sciences Limited is a Contract Research and Development Management Organization (CRDMO) providing services to the pharmaceutical and biotechnology sectors. The company's financial trajectory is supported by a debt-to-equity ratio of 0.2, and the offer consists solely of a fresh issue of Rs 8,000 crore with no Offer for Sale. The business is materially exposed to high-severity risks regarding customer concentration, as 64.51% to 67.15% of revenue is derived from CRO solutions, and geographic concentration, with 54.80% to 60.08% of revenue coming from North America. Additionally, the company faces risks related to the R&D budgets of innovator companies and the short contract termination cycles of biotechnology customers.
Partial analysis — some sections could not be read from the document (found: capitalisation, litigation, objects, price_basis, promoters, related_party, risks).
What stands out
Risk factor. A substantial portion of revenue (64.51%, 65.78%, 67.15% in Fiscals 2026, 2025, 2024) is derived from CRO solutions, making the business dependent on the continued outsourcing of R&D by innovator pharmaceutical and biotechnology companies.
Risk factor. A significant portion of revenue (54.80%, 60.08%, 55.19% in Fiscals 2026, 2025, 2024) is derived from North America, and 29.67%, 22.24%, 27.19% from Europe, exposing the business to adverse developments in these international markets.
Risk factor. The business is dependent on the R&D budgets of innovator pharmaceutical and biotechnology companies, which fluctuate due to changes in available resources, consolidation, spending priorities, and institutional budgetary policies.
Primarily fresh capital. 100% of the offer is fresh issue, so most proceeds fund the company.
Low leverage. Debt-to-equity of 0.20x.
How the offer is structured
Fresh issue
₹8.00k Cr
New capital into the company
OFS share
0%
- Repayment and/or pre-payment, in part or full, of certain borrowings availed by our Company and our Material Subsidiaries₹3.85k Cr
- Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad₹1.54k Cr
- Capital expenditure to be incurred by one of our Material Subsidiaries, namely, Aragen Biologics Private Limited for the facility in Bengaluru towards purchase of new equipment and machinery for the following: a. Expansion of biologics drug substance capacity (Drug Substance Expansion); and b. Establishment of biologics drug product fill and finish capability (Fill and Finish Line Establishment)₹710 Cr
- General corporate purposes
Promoters, litigation & related parties
Promoter (pre)
58.4%
Related-party
0.5%
Share of revenue
Except as disclosed in this section, there are no outstanding criminal proceedings, actions by regulatory or statutory authorities, claims and proceedings related to direct and indirect taxes, or other pending litigation involving the Company, its Subsidiaries, Promoters and Directors. There are no disciplinary actions, penalties, or show cause notices issued by SEBI or stock exchanges against Promoters in the last five financial years. There are no pending litigations involving Group Companies which have a material impact on the Company. There are no outstanding criminal proceedings or actions by statutory or regulatory authorities involving Key Managerial Personnel and members of Senior Management. The Materiality Threshold is ₹99.69 million.
Risks the company discloses
A substantial portion of revenue (64.51%, 65.78%, 67.15% in Fiscals 2026, 2025, 2024) is derived from CRO solutions, making the business dependent on the continued outsourcing of R&D by innovator pharmaceutical and biotechnology companies.(Customer Concentration)
A significant portion of revenue (54.80%, 60.08%, 55.19% in Fiscals 2026, 2025, 2024) is derived from North America, and 29.67%, 22.24%, 27.19% from Europe, exposing the business to adverse developments in these international markets.(Geographic Concentration)
The business is dependent on the R&D budgets of innovator pharmaceutical and biotechnology companies, which fluctuate due to changes in available resources, consolidation, spending priorities, and institutional budgetary policies.(Market Demand)
Biotechnology customers typically operate a limited number of programs and have shorter contract termination cycles of approximately one year, which may increase the variability of revenues and limit the ability to mitigate disruptions.(Contract Terms)
The business is exposed to risks arising from macroeconomic, regulatory, geopolitical, and industry-specific developments outside India, including changes in foreign laws, pricing pressures, and social or political conditions.(Regulatory & Geopolitical)
Currency fluctuations, inflation, and interest rate movements can affect operating costs and profitability, particularly for companies with significant export exposure.(Financial)
Certain global supply chain diversification trends, including strategies adopted by customers to reduce dependence on China, may influence demand for CRDMO service providers in India.(Supply Chain)
The business may have limited experience in servicing customers in new international markets, which may require management attention and resources.(Operational)